Merck (MRK) said the study met its primary endpoint of clinical remission according to the Modified Mayo Score at week 12, as well as key secondary endpoints
#GERMANY#EUROPE#MERCK & CO INC#MRK.US#MERCK KGAA#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#DAX 40 INDEX#MRK#US EQUITIES